Department of Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USA.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA.
Cells. 2019 Sep 21;8(10):1122. doi: 10.3390/cells8101122.
Animal studies have shown diabetes-induced lysyl oxidase (LOX) upregulation promotes blood-retinal-barrier breakdown and retinal vascular cell loss associated with diabetic retinopathy (DR). However, it is unclear whether changes in LOX expression contribute to the development and progression of DR. To determine if vitreous LOX levels are altered in patients with DR, 31 vitreous specimens from subjects with advanced proliferative DR (PDR), and 27 from non-diabetics were examined. The two groups were age- and gender-matched (57 ± 12 yrs vs. 53 ± 18 yrs; 19 males and 12 females vs. 17 males and 10 females). Vitreous samples obtained during vitrectomy were assessed for LOX levels using ELISA. LOX was detected in a larger number of PDR subjects (58%) than in non-diabetic subjects (15%). Additionally, ELISA measurements showed a significant increase in LOX levels in the diabetic subjects with PDR, compared to those of non-diabetic subjects (68.3 ± 112 ng/mL vs. 2.1 ± 8.2 ng/mL; < 0.01). No gender difference in vitreous LOX levels was observed in either the diabetic or non-diabetic groups. Findings support previous reports of increased LOX levels in retinas of diabetic animals and in retinal vascular cells in high glucose condition, raising the prospect of targeting LOX overexpression as a potential target for PDR treatment.
动物研究表明，糖尿病引起的赖氨酰氧化酶（LOX）上调促进了血视网膜屏障的破坏和与糖尿病视网膜病变（DR）相关的视网膜血管细胞的丧失。然而，尚不清楚 LOX 表达的变化是否有助于 DR 的发展和进展。为了确定 DR 患者的玻璃体 LOX 水平是否发生改变，检查了 31 例来自进展性增殖性 DR（PDR）患者的玻璃体标本和 27 例非糖尿病患者的玻璃体标本。两组在年龄和性别上相匹配（57 ± 12 岁比 53 ± 18 岁；19 名男性和 12 名女性比 17 名男性和 10 名女性）。通过 ELISA 评估玻璃体样本中的 LOX 水平。在更多的 PDR 患者（58%）中检测到 LOX，而非糖尿病患者（15%）。此外，ELISA 测量显示，与非糖尿病患者相比，PDR 糖尿病患者的 LOX 水平显著升高（68.3 ± 112 ng/mL 比 2.1 ± 8.2 ng/mL； < 0.01）。在糖尿病或非糖尿病组中，均未观察到玻璃体 LOX 水平的性别差异。这些发现支持了先前关于糖尿病动物视网膜和高葡萄糖条件下视网膜血管细胞中 LOX 水平升高的报道，这提高了将 LOX 过表达作为 PDR 治疗的潜在靶点的前景。
